Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06265688
PHASE1

First In Human Study of CX-2051 in Advanced Solid Tumors

Sponsor: CytomX Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Official title: An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2024-04-02

Completion Date

2029-03-31

Last Updated

2026-03-25

Healthy Volunteers

No

Interventions

DRUG

CX-2051

Investigational drug

DRUG

Bevacizumab

IV infusion

Locations (5)

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Carolina BioOncology Institute, PLLC

Huntersville, North Carolina, United States

Sarah Cannon Research Institute, LLC

Nashville, Tennessee, United States

START San Antonio LLC

San Antonio, Texas, United States